Last reviewed 2026-04-20 · How we verify

Adoptive Cellular Therapy

At a glance

Approved indications

No approved indications tracked.

Common side effects

• Lymphopenia
• Leukocytes (total WBC)
• Neutrophils/granulocytes (ANC/AGC)
• Platelets
• Febrile neutropenia
• Anaemia
• Dyspnea (shortness of breath)
• Nausea
• Chills
• Hypotension
• Hemoglobin
• Thrombocytopenia [4]

Key clinical trials

• Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic Leukemia (NA)
• A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab (PHASE2)
• Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation (PHASE1)
• Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies (PHASE1)
• A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2) (PHASE1, PHASE2)
• Safety and Efficacy of OBX-115 in Advanced Solid Tumors (PHASE1, PHASE2)
• CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (PHASE2)
• Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma Planned for Standard of Care CAR-T Cell Therapy (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Adoptive Cellular Therapy CI brief — competitive landscape report
• Adoptive Cellular Therapy updates RSS · CI watch RSS
• Cell Medica Ltd portfolio CI